Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS)
Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS)
复制标题
DOI：
10.1006/viro.1999.9765
复制
发表时间：
1999-07-05
期刊：
影响因子：
3.7
通讯作者：
Thipphawong, J
中科院分区：
文献类型：
--
作者：
Ennis, FA;Cruz, J;Thipphawong, J
需要提高亚单位疫苗在人类体内诱导CD8(+)CTL反应的能力，特别是用于预防在其主要中和抗体位点经历抗原变异的生物的疾病的疫苗，例如甲型流感病毒和人类免疫缺陷病毒。小鼠模型已经证明了交叉反应性CTL对甲型流感病毒抗原漂移的保护作用。我们测试了一种佐剂载体(Iscomatrix)在体外和在接种疫苗的人类中帮助人类抗原提呈细胞将福尔马林灭活的流感疫苗呈现给人CD8(+)CTL克隆的能力。一项随机、双盲、对照临床研究的结果表明，单剂制成ISCOM颗粒的疫苗可增加50%-60%的受试者的甲型流感病毒特异性CTL记忆，而标准流感疫苗受试者的这一比例为5%。(C)1999年学术出版社。
There is a need to improve the ability of subunit vaccines to induce CD8(+) CTL responses in humans, especially for vaccines used to prevent illness by organisms that undergo antigenic variation at their major neutralizing antibody sites, e.g., influenza A viruses and human immunodeficiency virus. Murine models have demonstrated the protective role of crossreactive CTL against influenza A virus antigenic drift. We tested the ability of an adjuvanted carrier (Iscomatrix) to help human antigen-presenting cells present formalin-killed influenza vaccine to human CD8(+) CTL clones in vitro and in vaccinated humans. The results of a randomized, double-blind, controlled clinical study demonstrate that a single dose of a vaccine formulated into Iscom particles increased influenza A virus-specific CTL memory in 50-60% of recipients, compared to 5% of the recipients of the standard influenza vaccine. (C) 1999 Academic Press.